CASI Pharmaceuticals (CASIF) Assets Average (2024 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Assets Average came in at $25.1 million in Q4 2025, down 57.28% YoY from $58.6 million in Q4 2024, and down 9.97% on a QoQ basis from $27.8 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Assets Average (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 2 years of Assets Average data on file, last reported at $25.1 million in Q4 2025.
- Quarterly Assets Average fell 57.28% year-over-year to $25.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.1 million (down 57.28% YoY) and the FY2025 annual result came in at $39.7 million, down 38.48% from the prior year.
- Assets Average declined to $25.1 million in Q4 2025, from $27.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $66.6 million in Q1 2024 to a low of $15.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 10.54 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.06 Mn |
| Sep 30, 2025 | 27.83 Mn |
| Jun 30, 2025 | 15.62 Mn |
| Mar 31, 2025 | 26.86 Mn |
| Dec 31, 2024 | 58.65 Mn |
| Sep 30, 2024 | 31.83 Mn |
| Jun 30, 2024 | 29.03 Mn |
| Mar 31, 2024 | 66.64 Mn |